Financial Ratios Exact Sciences Corporation
Equities
EXAS
US30063P1057
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 104.91 USD | +0.95% |
|
-.--% | +3.30% |
| Mar. 24 | Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Biotechnology Select Industry Index | CI |
| Mar. 24 | Exact Sciences Corporation(NasdaqCM:EXAS) dropped from S&P Global BMI Index | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -7.41 | -6.01 | -3.04 | -1.93 | -1.59 | |||||
Return on Total Capital | -8.3 | -6.88 | -3.44 | -2.2 | -1.86 | |||||
Return On Equity % | -21.18 | -19.39 | -6.6 | -37.09 | -8.66 | |||||
Return on Common Equity | -21.18 | -19.39 | -6.6 | -37.09 | -8.66 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 74.04 | 72.44 | 73.83 | 69.55 | 69.69 | |||||
SG&A Margin | 85.8 | 78.68 | 65.54 | 60.87 | 58.22 | |||||
EBITDA Margin % | -28.76 | -20.31 | -4.09 | 0.84 | 2.2 | |||||
EBITA Margin % | -33.59 | -25.11 | -8.67 | -3.5 | -1.65 | |||||
EBIT Margin % | -38.96 | -29.79 | -12.35 | -6.95 | -4.62 | |||||
Income From Continuing Operations Margin % | -33.71 | -29.91 | -8.17 | -37.29 | -6.4 | |||||
Net Income Margin % | -33.71 | -29.91 | -8.17 | -37.29 | -6.4 | |||||
Net Avail. For Common Margin % | -33.71 | -29.91 | -8.17 | -37.29 | -6.4 | |||||
Normalized Net Income Margin | -23.89 | -19.21 | -7.39 | -4.06 | -2.84 | |||||
Levered Free Cash Flow Margin | 0.76 | -12.84 | 3.67 | 2.04 | 8.68 | |||||
Unlevered Free Cash Flow Margin | 1.04 | -12.6 | 4.16 | 2.65 | 9.44 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.3 | 0.32 | 0.39 | 0.44 | 0.55 | |||||
Fixed Assets Turnover | 2.6 | 2.57 | 2.91 | 3.28 | 3.88 | |||||
Receivables Turnover (Average Receivables) | 7.86 | 11.13 | 13.82 | 12.19 | 11.86 | |||||
Inventory Turnover (Average Inventory) | 4.65 | 5.15 | 5.32 | 5.8 | 5.99 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.76 | 2.38 | 2.32 | 2.15 | 2.43 | |||||
Quick Ratio | 2.42 | 1.93 | 1.91 | 1.76 | 1.97 | |||||
Operating Cash Flow to Current Liabilities | -0.2 | -0.54 | 0.3 | 0.29 | 0.77 | |||||
Days Sales Outstanding (Average Receivables) | 46.46 | 32.81 | 26.4 | 30.02 | 30.78 | |||||
Days Outstanding Inventory (Average Inventory) | 78.47 | 70.93 | 68.55 | 63.14 | 60.93 | |||||
Average Days Payable Outstanding | 40.08 | 44.33 | 42.29 | 35.21 | 49.03 | |||||
Cash Conversion Cycle (Average Days) | 84.85 | 59.41 | 52.66 | 57.94 | 42.68 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 70.87 | 80.75 | 81.6 | 115.55 | 105.57 | |||||
Total Debt / Total Capital | 41.48 | 44.68 | 44.93 | 53.61 | 51.36 | |||||
LT Debt/Equity | 70.11 | 79.72 | 78.94 | 103.67 | 103.91 | |||||
Long-Term Debt / Total Capital | 41.03 | 44.1 | 43.47 | 48.09 | 50.55 | |||||
Total Liabilities / Total Assets | 49.32 | 51.13 | 51.4 | 59.48 | 59.03 | |||||
EBIT / Interest Expense | -37 | -31.62 | -15.88 | -7.1 | -3.81 | |||||
EBITDA / Interest Expense | -25.29 | -19.28 | -2.9 | 2.4 | 2.88 | |||||
(EBITDA - Capex) / Interest Expense | -32.59 | -30.21 | -9.29 | -2.63 | -0.54 | |||||
Total Debt / EBITDA | -5.1 | -6.49 | -45.47 | 42.73 | 22.34 | |||||
Net Debt / EBITDA | -2.91 | -4.82 | -31.69 | 26.75 | 13.83 | |||||
Total Debt / (EBITDA - Capex) | -3.96 | -4.14 | -14.21 | -39.08 | -119.76 | |||||
Net Debt / (EBITDA - Capex) | -2.26 | -3.08 | -9.9 | -24.46 | -74.18 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 18.49 | 17.95 | 19.93 | 10.36 | 17.69 | |||||
Gross Profit, 1 Yr. Growth % | 15.06 | 15.41 | 22.23 | 8.88 | 17.94 | |||||
EBITDA, 1 Yr. Growth % | 21.38 | -16.69 | -75.85 | -122.57 | 209.72 | |||||
EBITA, 1 Yr. Growth % | 21.47 | -11.8 | -58.61 | -55.4 | -44.71 | |||||
EBIT, 1 Yr. Growth % | 18.3 | -9.82 | -50.26 | -37.9 | -21.72 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -27.68 | 4.68 | -67.26 | 403.97 | -79.79 | |||||
Net Income, 1 Yr. Growth % | -27.68 | 4.68 | -67.26 | 403.97 | -79.79 | |||||
Normalized Net Income, 1 Yr. Growth % | 4.97 | -5.15 | -53.86 | -39.36 | -22.05 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -36.21 | 1.71 | -67.95 | 393.27 | -80.27 | |||||
Accounts Receivable, 1 Yr. Growth % | -7.09 | -27.05 | 28.84 | 22.27 | 19.96 | |||||
Inventory, 1 Yr. Growth % | 13.8 | 12.63 | 7.79 | 27.38 | 2.35 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 27.75 | 10.26 | -1 | -2.69 | 1.41 | |||||
Total Assets, 1 Yr. Growth % | 35.73 | -6.85 | 3.93 | -8.39 | -1.14 | |||||
Tangible Book Value, 1 Yr. Growth % | -798.17 | 21.8 | -11.67 | -12.42 | -8.95 | |||||
Common Equity, 1 Yr. Growth % | 51.53 | -10.17 | 3.36 | -23.62 | -0.05 | |||||
Cash From Operations, 1 Yr. Growth % | -174.91 | 118.67 | -169.83 | 34.86 | 133.42 | |||||
Capital Expenditures, 1 Yr. Growth % | 108.62 | 57.96 | -42.09 | 9.5 | -0.98 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -106.53 | -2.08K | -133.39 | -38.78 | 454.55 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -111.13 | -1.52K | -139.58 | -29.69 | 313.46 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 42.01 | 18.22 | 18.94 | 15.05 | 13.97 | |||||
Gross Profit, 2 Yr. CAGR % | 40.84 | 15.23 | 18.77 | 16.12 | 13.32 | |||||
EBITDA, 2 Yr. CAGR % | 66.4 | 0.6 | -56.09 | -77.01 | -16.39 | |||||
EBITA, 2 Yr. CAGR % | 65.1 | 3.54 | -40.67 | -57.57 | -50.35 | |||||
EBIT, 2 Yr. CAGR % | 71.61 | 3.32 | -34.07 | -45.01 | -30.28 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 67.19 | -12.99 | -41.46 | 28.46 | 0.93 | |||||
Net Income, 2 Yr. CAGR % | 67.19 | -12.99 | -41.46 | 28.46 | 0.93 | |||||
Normalized Net Income, 2 Yr. CAGR % | 28.9 | -0.2 | -34.9 | -47.64 | -29.31 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 46.33 | -19.45 | -42.9 | 25.66 | -1.39 | |||||
Accounts Receivable, 2 Yr. CAGR % | 28.91 | -17.67 | -3.05 | 25.51 | 21.11 | |||||
Inventory, 2 Yr. CAGR % | 30.42 | 13.21 | 10.19 | 17.18 | 14.18 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 14.42 | 19.51 | 5.09 | -1.85 | -0.66 | |||||
Total Assets, 2 Yr. CAGR % | 38.09 | 12.44 | -1.61 | -2.43 | -4.84 | |||||
Tangible Book Value, 2 Yr. CAGR % | 323.5 | 190.14 | 3.32 | -12.04 | -10.7 | |||||
Common Equity, 2 Yr. CAGR % | 21.68 | 16.67 | -3.64 | -11.15 | -12.63 | |||||
Cash From Operations, 2 Yr. CAGR % | -4.31 | 27.98 | 23.57 | -2.96 | 77.42 | |||||
Capital Expenditures, 2 Yr. CAGR % | -11.32 | 81.53 | -4.36 | -20.37 | 4.13 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -79.43 | 13.87 | 7.64 | -55.45 | 75.26 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -69.09 | 25.94 | 6.97 | -48.06 | 71.73 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 57.25 | 33.49 | 18.79 | 16.01 | 15.92 | |||||
Gross Profit, 3 Yr. CAGR % | 57.04 | 31.79 | 17.52 | 13.61 | 16.72 | |||||
EBITDA, 3 Yr. CAGR % | 55.03 | 32.13 | -37.48 | -64.83 | -45.3 | |||||
EBITA, 3 Yr. CAGR % | 55.8 | 33.96 | -23.73 | -46.06 | -53.66 | |||||
EBIT, 3 Yr. CAGR % | 62.83 | 38.49 | -19.03 | -35.37 | -38.14 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 50.38 | 43.03 | -37.18 | 19.99 | -30.65 | |||||
Net Income, 3 Yr. CAGR % | 50.38 | 43.03 | -37.18 | 19.99 | -30.65 | |||||
Normalized Net Income, 3 Yr. CAGR % | 56.84 | 16.37 | -22.83 | -36.42 | -39.09 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 34.36 | 29.62 | -40.75 | 17.16 | -32.22 | |||||
Accounts Receivable, 3 Yr. CAGR % | 68.44 | 6.63 | -4.42 | 4.74 | 23.63 | |||||
Inventory, 3 Yr. CAGR % | 38.94 | 24.2 | 11.38 | 15.64 | 12.01 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 45.92 | 13.54 | 12.68 | 2.43 | -0.77 | |||||
Total Assets, 3 Yr. CAGR % | 63.69 | 21.1 | 9.53 | -3.93 | -2 | |||||
Tangible Book Value, 3 Yr. CAGR % | 18.37 | 178.61 | 94.67 | -2.22 | -11.02 | |||||
Common Equity, 3 Yr. CAGR % | 70.71 | 9.97 | 12.05 | -10.83 | -7.6 | |||||
Cash From Operations, 3 Yr. CAGR % | 14.04 | 26.04 | 4.58 | 27.23 | 30.02 | |||||
Capital Expenditures, 3 Yr. CAGR % | -3.29 | 7.5 | 24.04 | 0.05 | -14.37 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -53.67 | -5.71 | -23.68 | -10.82 | -0.15 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -49.28 | 10.79 | -14.38 | -7 | 4.2 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 77.83 | 50.94 | 40.63 | 25.78 | 16.84 | |||||
Gross Profit, 5 Yr. CAGR % | 89.05 | 51.74 | 40.44 | 23.81 | 14.76 | |||||
EBITDA, 5 Yr. CAGR % | 26.4 | 32.73 | -5.6 | -33.95 | -29.77 | |||||
EBITA, 5 Yr. CAGR % | 28.59 | 34.86 | 6.66 | -15 | -35.76 | |||||
EBIT, 5 Yr. CAGR % | 32.43 | 39.32 | 14.13 | -3.88 | -23.73 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 28.93 | 40.37 | 3.11 | 37.01 | -24.06 | |||||
Net Income, 5 Yr. CAGR % | 28.93 | 40.37 | 3.11 | 37.01 | -24.06 | |||||
Normalized Net Income, 5 Yr. CAGR % | 32.21 | 41.09 | 11.04 | -15.1 | -25.49 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 16.3 | 29.02 | -4.59 | 28.05 | -27.36 | |||||
Accounts Receivable, 5 Yr. CAGR % | 90.99 | 43.01 | 35.05 | 13.81 | 5.07 | |||||
Inventory, 5 Yr. CAGR % | 72.71 | 35.36 | 26.63 | 21.34 | 12.49 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 82.02 | 60.5 | 28.32 | 7.37 | 7.14 | |||||
Total Assets, 5 Yr. CAGR % | 77.72 | 59.75 | 33.54 | 11.08 | 3.54 | |||||
Tangible Book Value, 5 Yr. CAGR % | 25.82 | 20.66 | 11.87 | 75.39 | 42.53 | |||||
Common Equity, 5 Yr. CAGR % | 58.82 | 42.36 | 35.8 | 0.98 | 1.44 | |||||
Cash From Operations, 5 Yr. CAGR % | -4.7 | 25.53 | 17.76 | 13.52 | 29.2 | |||||
Capital Expenditures, 5 Yr. CAGR % | 55.67 | 34.63 | -3.72 | -4.66 | 15.65 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -30.76 | 23.08 | -7.54 | -29.36 | 6.42 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -26.29 | 22.64 | -5.97 | -17.66 | 13.11 |
- Stock Market
- Equities
- EXAS Stock
- Financials Exact Sciences Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















